Silence Therapeutics plc
SLNCF
$4.00
-$1.50-27.27%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 422.00K | 34.00K | 159.00K | 224.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 422.00K | 34.00K | 159.00K | 224.00K |
| Cost of Revenue | -- | 11.00K | 12.00K | 64.00K | 85.00K |
| Gross Profit | -- | 411.00K | 22.00K | 95.00K | 139.00K |
| SG&A Expenses | 4.72M | 7.03M | 3.73M | 5.80M | 5.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.09M | 15.47M | 12.67M | 23.82M | 20.49M |
| Operating Income | -13.09M | -15.05M | -12.63M | -23.66M | -20.27M |
| Income Before Tax | -12.27M | -14.96M | -11.77M | -20.96M | -27.34M |
| Income Tax Expenses | 1.00K | -- | 0.00 | 1.00K | 10.00K |
| Earnings from Continuing Operations | -12.27M | -14.96M | -11.77M | -20.96M | -27.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.27M | -14.96M | -11.77M | -20.96M | -27.35M |
| EBIT | -13.09M | -15.05M | -12.63M | -23.66M | -20.27M |
| EBITDA | -12.98M | -14.94M | -12.52M | -23.51M | -20.12M |
| EPS Basic | -0.78 | -0.95 | -0.75 | -1.33 | -1.74 |
| Normalized Basic EPS | -0.16 | -0.20 | -0.16 | -0.28 | -0.34 |
| EPS Diluted | -0.78 | -0.95 | -0.75 | -1.33 | -1.74 |
| Normalized Diluted EPS | -0.16 | -0.20 | -0.16 | -0.28 | -0.34 |
| Average Basic Shares Outstanding | 47.24M | 47.23M | 47.23M | 47.23M | 47.23M |
| Average Diluted Shares Outstanding | 15.75M | 15.74M | 15.74M | 15.74M | 15.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |